SB Relafen Data Do Not Support COX-2 Selectivity, FDA Warns
Executive Summary
FDA has escalated its attempts to halt SmithKline Beecham's Relafen (nabumetone) promotions implying COX-2 selectivity for the arthritis drug with a March 13 ad division warning letter.